• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

c-Myc 对人肝细胞癌中 GPC3 的致癌激活作用。

Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma.

机构信息

Beijing Institute of Liver Disease, Beijing, China.

出版信息

Hepatology. 2012 Oct;56(4):1380-90. doi: 10.1002/hep.25891.

DOI:10.1002/hep.25891
PMID:22706665
Abstract

UNLABELLED

Glypican-3 (GPC3) is a heparan sulfate proteoglycan that has an important role in cell growth and differentiation, and its function in tumorigenesis is tissue-dependent. In hepatocellular carcinoma (HCC), the overexpression of GPC3 has been demonstrated to be a reliable diagnostic indicator. However, the mechanisms that regulate the expression and function of GPC3 remain unclear. The oncoprotein c-Myc is a transcription factor that plays a significant role in more than 50% of human tumors. We report here that GPC3 is a transcriptional target of c-Myc and that the expression of c-Myc is also regulated by GPC3, thus forming a positive feedback signaling loop. We found that the overexpression of c-Myc could induce GPC3 promoter-dependent luciferase activity in luciferase reporter experiments. Furthermore, mutational analysis identified c-Myc-binding sites within the GPC3 promoter. The exogenous overexpression of c-Myc increased the endogenous messenger RNA (mRNA) and protein levels of GPC3. Chromatin immunoprecipitation experiments revealed the binding of c-Myc to the endogenous GPC3 promoter, indicating that c-Myc can directly transcriptionally activate GPC3. Interestingly, GPC3 can also elevate c-Myc expression. Overexpression of GPC3 increased c-Myc protein levels, whereas the knockdown of GPC3 reduced c-Myc expression levels. Lastly, the elevated levels of c-Myc correlate with the overexpression of GPC3 in human HCC samples.

CONCLUSION

These data provide new mechanistic insight into the roles of GPC3 and of c-Myc in the development of HCC.

摘要

未标记

Glypican-3(GPC3)是一种硫酸乙酰肝素蛋白聚糖,在细胞生长和分化中具有重要作用,其在肿瘤发生中的作用具有组织依赖性。在肝细胞癌(HCC)中,已经证明 GPC3 的过表达是一种可靠的诊断指标。然而,调节 GPC3 的表达和功能的机制尚不清楚。癌蛋白 c-Myc 是一种转录因子,在超过 50%的人类肿瘤中发挥重要作用。我们在这里报告 GPC3 是 c-Myc 的转录靶标,并且 c-Myc 的表达也受 GPC3 调节,从而形成正反馈信号环路。我们发现 c-Myc 的过表达可以在荧光素酶报告实验中诱导 GPC3 启动子依赖性荧光素酶活性。此外,突变分析确定了 GPC3 启动子内的 c-Myc 结合位点。外源性过表达 c-Myc 增加了内源性信使 RNA(mRNA)和 GPC3 蛋白水平。染色质免疫沉淀实验显示 c-Myc 与内源性 GPC3 启动子结合,表明 c-Myc 可以直接转录激活 GPC3。有趣的是,GPC3 也可以提高 c-Myc 的表达。GPC3 的过表达增加了 c-Myc 蛋白水平,而 GPC3 的敲低则降低了 c-Myc 表达水平。最后,c-Myc 的升高水平与人类 HCC 样本中 GPC3 的过表达相关。

结论

这些数据为 GPC3 和 c-Myc 在 HCC 发展中的作用提供了新的机制见解。

相似文献

1
Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma.c-Myc 对人肝细胞癌中 GPC3 的致癌激活作用。
Hepatology. 2012 Oct;56(4):1380-90. doi: 10.1002/hep.25891.
2
Reduced nucleic ZHX2 involves in oncogenic activation of glypican 3 in human hepatocellular carcinoma.核酸减少的ZHX2参与人肝细胞癌中磷脂酰肌醇蛋白聚糖3的致癌激活。
Int J Biochem Cell Biol. 2014 Oct;55:129-35. doi: 10.1016/j.biocel.2014.08.021. Epub 2014 Sep 6.
3
A functional screening identifies five microRNAs controlling glypican-3: role of miR-1271 down-regulation in hepatocellular carcinoma.一项功能筛选鉴定了五个调控甘胆酸蛋白-3 的 microRNAs:miR-1271 下调在肝细胞癌中的作用。
Hepatology. 2013 Jan;57(1):195-204. doi: 10.1002/hep.25994.
4
Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway.Glypican-3 通过 ERK 信号通路促进肝癌细胞的上皮间质转化。
Int J Oncol. 2015 Mar;46(3):1275-85. doi: 10.3892/ijo.2015.2827. Epub 2015 Jan 9.
5
Phosphorylation regulates Myc expression via prolonged activation of the mitogen-activated protein kinase pathway.磷酸化通过丝裂原活化蛋白激酶途径的长期激活来调节Myc表达。
J Cell Physiol. 2006 Jul;208(1):133-40. doi: 10.1002/jcp.20649.
6
Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.长链非编码RNA磷脂酰肌醇蛋白聚糖3(GPC3)反义转录本1通过表观遗传激活GPC3促进肝细胞癌进展。
FEBS J. 2016 Oct;283(20):3739-3754. doi: 10.1111/febs.13839. Epub 2016 Sep 21.
7
Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling.磷脂酰肌醇蛋白聚糖-3在肝细胞癌中过表达,可调节成纤维细胞生长因子2(FGF2)和骨形态发生蛋白7(BMP-7)信号通路。
Int J Cancer. 2003 Feb 10;103(4):455-65. doi: 10.1002/ijc.10856.
8
Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line.RNA 干扰抑制 Glypican-3 表达影响 MHCC97-H 人肝癌细胞系的生长和侵袭能力。
Int J Mol Med. 2011 Oct;28(4):497-503. doi: 10.3892/ijmm.2011.704. Epub 2011 May 20.
9
Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.评估抗磷脂酰肌醇蛋白聚糖-3疗法作为改善肝细胞癌肝组织损伤的一个有前景的靶点。
Eur J Pharmacol. 2015 Jan 5;746:353-62. doi: 10.1016/j.ejphar.2014.11.008. Epub 2014 Nov 18.
10
Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.肝脏细针穿刺抽吸物中的磷脂酰肌醇蛋白聚糖-3免疫细胞化学:一种有助于鉴别肝脏良恶性病变的新型染色方法。
Cancer. 2007 Oct 25;111(5):316-22. doi: 10.1002/cncr.22954.

引用本文的文献

1
Investigation and Distinction of Energy Metabolism in Proliferating Hepatocytes and Hepatocellular Carcinoma Cells.增殖性肝细胞与肝癌细胞能量代谢的研究与区分
Cells. 2025 Aug 14;14(16):1254. doi: 10.3390/cells14161254.
2
Targeting Glypican-3 for Liver Cancer Therapy: Clinical Applications and Detection Methods.靶向磷脂酰肌醇蛋白聚糖-3用于肝癌治疗:临床应用与检测方法
J Clin Transl Hepatol. 2025 Aug 28;13(8):665-681. doi: 10.14218/JCTH.2025.00099. Epub 2025 Aug 7.
3
Diagnosis of hepatocellular carcinoma using liquid biopsy-based biomarkers: a systematic review and network meta-analysis.
基于液体活检生物标志物诊断肝细胞癌:系统评价与网状Meta分析
Front Oncol. 2025 Jan 28;14:1483521. doi: 10.3389/fonc.2024.1483521. eCollection 2024.
4
Exploring Glypican-3 targeted CAR-NK treatment and potential therapy resistance in hepatocellular carcinoma.探索磷脂酰肌醇蛋白聚糖-3靶向嵌合抗原受体自然杀伤细胞疗法及肝细胞癌潜在的治疗耐药性
PLoS One. 2025 Jan 22;20(1):e0317401. doi: 10.1371/journal.pone.0317401. eCollection 2025.
5
CAR-T cell therapy for hepatocellular carcinoma: current trends and challenges.嵌合抗原受体 T 细胞疗法治疗肝细胞癌:现状与挑战。
Front Immunol. 2024 Nov 6;15:1489649. doi: 10.3389/fimmu.2024.1489649. eCollection 2024.
6
20(S)-Ginsenoside Rh2 inhibits hepatocellular carcinoma by suppressing angiogenesis and the GPC3-mediated Wnt/β‑catenin signaling pathway.20(S)-人参皂苷 Rh2 通过抑制血管生成和 GPC3 介导的 Wnt/β-连环蛋白信号通路抑制肝细胞癌。
Acta Biochim Biophys Sin (Shanghai). 2024 May 25;56(5):688-696. doi: 10.3724/abbs.2024038.
7
GPC3 Promotes Lung Squamous Cell Carcinoma Progression and HLA-A2-Restricted GPC3 Antigenic Peptide-Modified Dendritic Cell-Induced Cytotoxic T Lymphocytes to Kill Lung Squamous Cell Carcinoma Cells.GPC3 促进肺鳞状细胞癌的进展和 HLA-A2 限制性 GPC3 抗原肽修饰的树突状细胞诱导的细胞毒性 T 淋巴细胞杀伤肺鳞状细胞癌细胞。
J Immunol Res. 2023 Nov 6;2023:5532617. doi: 10.1155/2023/5532617. eCollection 2023.
8
Identification and validation of microtubule depolymerizing agent, CYT997, as a potential drug candidate for hepatocellular carcinoma.鉴定和验证微管去聚合剂 CYT997 作为治疗肝细胞癌的潜在药物候选物。
Liver Int. 2023 Dec;43(12):2794-2807. doi: 10.1111/liv.15756. Epub 2023 Oct 13.
9
MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages.MYC 过表达驱动肝细胞癌中的免疫逃逸,通过恢复促炎巨噬细胞可使其逆转。
Cancer Res. 2023 Feb 15;83(4):626-640. doi: 10.1158/0008-5472.CAN-22-0232.
10
Glypican-3 (GPC3) is associated with MCPyV-negative status and impaired outcome in Merkel cell carcinoma.Glypican-3 (GPC3) 与 Merkel 细胞癌中 MCPyV 阴性状态和不良预后相关。
Oncotarget. 2022 Aug 3;13:960-967. doi: 10.18632/oncotarget.28260. eCollection 2022.